Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239525 | 0.91 | UTS2R (0.43) | POLBUTS2RSLC6A9SLC6A5KMT2A | |
| SCHEMBL3237287 | 0.88 | SLC6A9 (0.45) | UTS2RSLC6A9LMNASLC6A5 | |
| SCHEMBL3239348 | 0.86 | KLRK1 (0.41) | SLC6A9 | |
| SCHEMBL3244640 | 0.85 | SLC6A9 (0.42) | UTS2RSLC6A9HSD17B10LMNASLC6A5 | |
| SCHEMBL3239596 | 0.84 | CNR1 (0.41) | SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL3236708 | 0.83 | SLC6A9 (0.48) | SLC6A9SLC6A5MEN1KMT2A | |
| SCHEMBL3232935 | 0.82 | SLC6A9 (0.47) | UTS2RSLC6A9LMNASLC6A5KMT2A | |
| SCHEMBL3243825 | 0.82 | TAS1R3 (0.42) | SLC6A9MEN1KMT2A | |
| SCHEMBL3239983 | 0.82 | UTS2R (0.42) | UTS2RSLC6A9MEN1KMT2A | |
| SCHEMBL13780494 | 0.81 | SLC6A9 (0.59) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | POLB 2897/4885UTS2R 3013/4885SLC6A9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.